'Reboot' drug reduces risk of MS relapses
Published 01/11/2012 | 05:00
A DRUG which is said to "reboot" the immune system has been shown to be an effective treatment for multiple sclerosis (MS), a study has found.
The results of trials are so encouraging that the MS Society is campaigning for the drug to become available on the NHS.
The research, published in 'The Lancet', showed that alemtuzumab significantly reduced the number of relapses by MS sufferers compared to the current drug, interferon beta-1a.
Over a two-year period, 65pc of patients on alemtuzumab, compared with 47pc on interferon, did not relapse.